MDR_Button Contact_Button News_Button  

Company Info

CBA Pharma, Inc. is a specialty pharmaceutical company headquartered in Lexington, Kentucky.

CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.

Multiple Drug Resistance (MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.

CBA Pharma Vision Statement
CBA Pharma's vision is to provide hope and opportunity for a normal life span with an improved quality of life to people with life threatening disease.

The unifying principle of "Many Minds, One Heart"® is the core of the philosophical foundation of CBA Pharma. It best reflects the pioneering research and product development successes achieved over the past decade leading to the creation of this company. It signifies the focused intent of many individuals (employees, shareholders, consultants, clinical investigators, etc.) toward a common vision.

"Many Minds, One Heart"®
Our unifying principle means that we, as a company, collaborate the intelligence and creativity of the minds in our entire organization and our many alliances toward the single heartfelt intent of helping others to heal their disease.

 

 
 
Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.

 

© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions